by Dennis Crouch Amgen Inc. v. Sanofi-Aventis (Fed. Cir. 2021) Patent claims typically cover an infinite number of potential infringing embodiments.  This seemingly renders true full-scope enablement an impossible task.  But the metaphysics are an illusion.  If we want valid patents, then there has to be some “good enough” threshold for enablement. The focus in Amgen is … Continue reading Amgen v. Sanofi: Who Decides Full Scope Enablement